Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases

Journal of Inherited Metabolic Disease

Volumn 34, Issue 2, 2011, Pages 499-508

  Langford Smith, Kia Jane ^a   Mercer, Jean ^b   Petty, June ^b   Tylee, Karen ^b   Church, Heather ^b   Roberts, Jane ^b   Moss, Gill ^b   Jones, Simon ^b   Wynn, Rob ^c   Wraith, J Ed ^b   Bigger, Brian W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; GALSULFASE; GLYCOSAMINOGLYCAN; HEPARIN COFACTOR II; IDURONATE 2 SULFATASE; LARONIDASE; THROMBIN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CHILD; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MORQUIO SYNDROME; MOUSE; NONHUMAN; PEDIATRIC HOSPITAL; SHORT COURSE THERAPY; TREATMENT RESPONSE; URINALYSIS; URINE LEVEL;

ANIMALS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHONDROITIN SULFATES; DERMATAN SULFATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSAMINOGLYCANS; HEPARIN COFACTOR II; HUMANS; INFANT; INFANT, NEWBORN; MICE; NEONATAL SCREENING; THROMBIN; TREATMENT OUTCOME;

EID: 79955694295     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9254-8     Document Type: Article

References (24)

1. Boelens, J. J., Rocha, V., Aldenhoven, M., et al. (2009). Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant, 15(5), 618-625.
2. Canal MM, Wilkinson FL, Cooper JD, Wraith JE, Wynn R, Bigger BW (2010) Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB. Behav Brain Res 209(2): 212-20.
3. Church, H., Tylee, K., Cooper, A., et al. (2007). Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant, 39(4), 207-210.
4. Decker, C., Yu, Z. F., Giugliani, R., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human Nacetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med, 3(2), 89-100.
5. Escolar, M. L., Poe, M. D., Provenzale, J. M., et al. (2005). Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med, 352(20), 2069-2081. (Pubitemid 40664308)
6. Harmatz, P., Giugliani, R., Schwartz, I. V., et al. (2008). Long-term followup of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab, 94(4), 469-475.
7. Jones, S. A., Almassy, Z., Beck, M., et al. (2009). Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis, 32(4), 534-543.
8. Krivit, W. (2002). Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr, 49, 359-378.
9. Krivit, W., Pierpont, M. E., Ayaz, K., et al. (1984). Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med, 311(25), 1606-1611. (Pubitemid 15175201)
10. Langford-Smith, K., Arasaradnam, M., Wraith, J. E., Wynn, R., & Bigger, B. W. (2010). Evaluation of heparin cofactor IIthrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Mol Genet Metab, 99(3), 269-274.
11. Malinowska, M., Wilkinson, F. L., Bennett, W., et al. (2009). Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab, 98(3), 235-242.
12. Matzner, U., Matthes, F., Weigelt, C., et al. (2008). Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease. J Mol Med, 86(4), 433-442.
13. Meikle, P. J., & Hopwood, J. J. (2003). Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur J Pediatr, 162(Suppl 1), S34-S37. (Pubitemid 38064742)
14. Meyer, A., Kossow, K., Gal, A., et al. (2007). Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics, 120(5), e1255-e1261.
15. Montano, A. M., Tomatsu, S., Gottesman, G. S., Smith, M., & Orii, T. (2007). International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis, 30 (2), 165-174. (Pubitemid 46487997)
16. Peters, C., Shapiro, E. G., Anderson, J., et al. (1998). Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood, 91(7), 2601-2608.
17. Peters, C., & Steward, C. G. (2003). Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant, 31(4), 229-239. (Pubitemid 36336225)
18. Randall, D. R., Colobong, K. E., Hemmelgarn, H., et al. (2008). Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol Genet Metab, 94(4), 456-461.
19. Randall, D. R., Sinclair, G. B., Colobong, K. E., Hetty, E., & Clarke, L. A. (2006). Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab, 88(3), 235-243. (Pubitemid 43963434)
20. Vellodi, A., Young, E. P., Cooper, A., et al. (1997). Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child, 76(2), 92-99. (Pubitemid 27086874)
21. Wraith, J. E. (2008). Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta Paediatr Suppl, 97(457), 76-78.
22. Wraith, J. E., Clarke, L. A., Beck, M., et al. (2004). Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr, 144(5), 581-588. (Pubitemid 38594757)
23. Wynn, R. F., Wraith, J. E., Mercer, J., et al. (2009). Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr, 154(4), 609-611.
24. Yamada, Y., Kato, K., Sukegawa, K., et al. (1998). Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant, 21(6), 629-634. (Pubitemid 28138265)